CYP2C19 is a cytochrome P450 enzyme primarily involved in the metabolism of drugs such as clopidogrel, proton pump inhibitors, and certain antidepressants. Its direct role in blood sugar regulation is not established. Some research has explored associations between CYP2C19 polymorphisms and type 2 diabetes risk or metformin response, but findings are inconsistent and lack clinical significance. The provided context mentions CYP2C19*2 (rs4244285) as a poor metabolizer for specific drugs, not for blood glucose. Evidence for a role in glucose homeostasis is weak, based on mechanistic speculation or small association studies. Consumers should not rely on DTC genetic tests to explain blood sugar issues. For known CYP2C19 variants, medical consultation regarding drug dosing is appropriate, but not for blood sugar management.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-2421fa318c413945dc98fc13